专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20080312411A1 Use of Activated Polymers for Separation of Protein and Polypeptide Multimers 审中-公开
标题翻译：使用活性聚合物分离蛋白质和多肽多聚体
公开(公告)号：US20080312411A1
公开(公告)日：2008-12-18
申请号：US11884300
申请日：2006-02-15
申请人： Andreas Wolf , Patrick Hoffmann , Julia Hepp Nee Henckel , Tobias Raum
发明人： Andreas Wolf , Patrick Hoffmann , Julia Hepp Nee Henckel , Tobias Raum
IPC分类号： C07K1/14
CPC分类号： C07K16/00 , A61K47/60 , C07K1/1077 , C07K2317/622
摘要： The invention relates to a use of an activated polymer to separate a non-covalently associated polypeptide multimer comprising multiple polypeptide subunits into multiple polypeptide subunits.
摘要翻译：本发明涉及使用活化聚合物将包含多个多肽亚基的非共价相关多肽的多聚体分离成多个多肽亚基。

12. 发明申请

US20110256137A1 PHARMACEUTICAL COMPOSITION COMPRISING A BISPECIFIC ANTIBODY FOR EPCAM 有权
标题翻译：包含EPCAM的双重抗体的药物组合物
公开(公告)号：US20110256137A1
公开(公告)日：2011-10-20
申请号：US13079453
申请日：2011-04-04
申请人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Patrick Bauerle
发明人： Peter Kufer , Meera Berry , Sonja Offner , Klaus Brischwein , Andreas Wolf , Tobias Raum , Birgit Kohleisen , Ulla Lenkkeri-Schutz , Patrick Bauerle
IPC分类号： A61K39/395 , C07H21/00 , A61P35/00 , C12P21/02 , C12N5/10 , C12N1/00 , C07K16/28 , C12N15/63
CPC分类号： C07K16/30 , A61K2039/505 , C07K16/2809 , C07K16/3076 , C07K2317/31 , C07K2317/622 , C07K2317/92 , C07K2319/00 , Y10S435/81 , Y10S435/975
摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.
摘要翻译：本发明提供包含双特异性单链抗体构建体的药物组合物。所述双特异性单链抗体构建体的特征在于包含至少两个结构域或由至少两个结构域组成，其中所述至少两个结构域之一特异性结合人EpCAM并且包含至少一个CDR-H3区，其包含氨基酸序列NXID抗原和第二结构域结合人CD3抗原。本发明进一步提供了制备本发明的药物组合物的方法，一种预防，治疗或改善肿瘤疾病的方法，以及所公开的双特异性单链抗体构建体的用途和相应的手段，用于预防，治疗或改善肿瘤疾病

13. 发明授权

US08236308B2 Composition comprising cross-species-specific antibodies and uses thereof 有权
标题翻译：包含交叉物种特异性抗体的组合物及其用途
公开(公告)号：US08236308B2
公开(公告)日：2012-08-07
申请号：US12083351
申请日：2006-10-10
申请人： Roman Kischel , Tobias Raum , Bernd Schlereth , Doris Rau , Ronny Cierpka , Peter Kufer
发明人： Roman Kischel , Tobias Raum , Bernd Schlereth , Doris Rau , Ronny Cierpka , Peter Kufer
IPC分类号： A61K39/395
CPC分类号： A61K39/39558 , A61K45/06 , A61K2039/505 , C07K16/2809 , C07K16/30 , C07K16/40 , C07K16/468 , C07K2317/31 , C07K2317/34 , C07K2317/56 , C07K2317/622
摘要： The present invention relates to uses of bispecific antibodies exhibiting cross-species specificity for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of the same in non-human species and humans. The present invention moreover relates to methods for evaluating the in vivo safety and/or activity and/or pharmacokinetic profile of said bispecific anti-bodies exhibiting cross-species specificity. The present invention also relates to methods of measuring the biological activity and/or efficacy of such bispecific antibodies exhibiting cross-species specificity. In addition, the present invention relates to pharmaceutical compositions comprising bispecific single chain antibodies exhibiting cross-species specificity and to methods for the preparation of pharmaceutical compositions comprising said bispecific single chain antibodies exhibiting cross-species specificity for the treatment of diseases.
摘要翻译：本发明涉及显示跨物种特异性的双特异性抗体用于评估其在非人物种和人中的体内安全性和/或其活性和/或药代动力学特征的用途。本发明还涉及用于评估展示跨物种特异性的所述双特异性抗体的体内安全性和/或活性和/或药代动力学特征的方法。本发明还涉及测量显示跨物种特异性的这种双特异性抗体的生物活性和/或功效的方法。此外，本发明涉及包含显示跨物种特异性的双特异性单链抗体的药物组合物和用于制备药物组合物的方法，所述药物组合物包含显示针对疾病治疗疾病的跨物种特异性的所述双特异性单链抗体。

14. 发明申请

US20110275787A1 CROSS-SPECIES-SPECIFIC SINGLE DOMAIN BISPECIFIC SINGLE CHAIN ANTIBODY 审中-公开
标题翻译：跨物种特异性单链单链单链抗体
公开(公告)号：US20110275787A1
公开(公告)日：2011-11-10
申请号：US13122280
申请日：2009-10-01
申请人： Peter Kufer , Tobias Raum
发明人： Peter Kufer , Tobias Raum
IPC分类号： C07K16/18 , C07K14/435
CPC分类号： C07K16/2863 , C07K16/2803 , C07K16/2878 , C07K16/2884 , C07K2317/31 , C07K2317/34
摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ε (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
摘要翻译：本发明涉及双特异性单链抗体分子，其包含由能够结合人和非黑猩猩灵长类CD3ε链的表位的一个抗体可变结构域组成的第一结合结构域，其中所述表位是氨基酸序列的一部分包括在由SEQ ID NOs组成的组中。 2,4,6和8以及能够结合人和非黑猩猩灵长类动物靶标抗原的表位的第二结合结构域。本发明还涉及双特异性单链抗体分子，其包含能够结合人和非黑猩猩灵长类CD3抗原表位的第一结合结构域; （ε）链，其中所述表位是包含在SEQ ID NO中的氨基酸序列的一部分。 2,4,6和8以及由能够与人的表位结合的一个抗体可变结构域和非黑猩猩灵长类动物靶标抗原组成的第二结合结构域。本发明还提供了编码所述双特异性单链抗体分子以及载体和宿主细胞的核酸及其生产方法。本发明还涉及包含所述双特异性单链抗体分子的药物组合物和所述双特异性单链抗体分子的医学应用。

15. 发明申请

US20080317746A1 Anti-Il2 Antibodies 有权
标题翻译：抗Il2抗体
公开(公告)号：US20080317746A1
公开(公告)日：2008-12-25
申请号：US11916017
申请日：2006-05-31
申请人： Patrick Bauerle , John Lumsden , Stefan Pflanz , Tobias Raum , Jorg Volkland
发明人： Patrick Bauerle , John Lumsden , Stefan Pflanz , Tobias Raum , Jorg Volkland
IPC分类号： A61K39/395 , C07K16/24 , A61P9/10 , A61P35/00 , A61K48/00 , A61K31/711 , A61P37/02 , C07H21/04
CPC分类号： C07K14/55 , C07K16/246 , C07K2317/24 , C07K2317/567 , C07K2317/73 , C07K2317/76
摘要： The invention relates to a humanized monoclonal antibody or fragment thereof which specifically binds to human interleukin-2 (IL2), wherein said humanized monoclonal antibody neutralizes the activity of human IL2 by binding to said human IL2 prior to, during, and/or subsequent to the binding of said human IL2 to the human IL2-receptor, and wherein the light chain variable region of said humanized monoclonal antibody comprises in its second framework region the contiguous amino acid sequence KAPKA at amino acid positions 42-46.
摘要翻译：本发明涉及特异性结合人白细胞介素-2（IL2）的人源化单克隆抗体或其片段，其中所述人源化单克隆抗体通过在之前，期间和/或之后与所述人IL2结合而中和人IL2的活性所述人IL2与人IL2受体的结合，并且其中所述人源化单克隆抗体的轻链可变区在其第二框架区域中包含氨基酸位置42-46处的连续氨基酸序列KAPKA。

16. 发明授权

US07435549B1 Method of identifying binding site domains that retain the capacity of binding to an epitope 有权
标题翻译：鉴定保留与表位结合的能力的结合位点结构域的方法
公开(公告)号：US07435549B1
公开(公告)日：2008-10-14
申请号：US09554465
申请日：1998-11-16
申请人： Peter Kufer , Tobias Raum , Katrin Borschert , Florian Zettl , Ralf Lutterbuse
发明人： Peter Kufer , Tobias Raum , Katrin Borschert , Florian Zettl , Ralf Lutterbuse
IPC分类号： G01N33/53
CPC分类号： C40B40/02 , A61K38/00 , C07K14/70525 , C07K14/70528 , C07K14/70532 , C07K16/3046 , C07K2319/00 , C12N15/1037
摘要： The present invention relates to a method of identifying binding site domains that retain the capacity of binding to an epitope when positioned C-terminal of at least one further domain in a recombinant bi- or multivalent polypeptide. The present invention further relates to a kit comprising components such as panels of recombinant vectors of bacterial libraries transfected with a panel of recombinant vectors which is useful in carrying out the method of the invention. Furthermore, binding site domains and fusion proteins obtainable by the method of the invention as well as antibody-like molecules comprising such domains and proteins are described. Furthermore, pharmaceutical and diagnostic compositions containing the above-described fusion proteins and polypeptides are provided.
摘要翻译：本发明涉及一种鉴定结合位点结构域的方法，当定位在重组双或多价多肽中的至少另一个结构域的C-末端时，其保留与表位结合的能力。本发明还涉及一种试剂盒，其包含诸如用于实施本发明的方法的重组载体的一组重组载体转染的细菌文库的重组载体的片段的组分。此外，描述了可通过本发明的方法获得的结合位点结构域和融合蛋白以及包含这种结构域和蛋白质的抗体样分子。此外，提供含有上述融合蛋白和多肽的药物和诊断组合物。

17. 发明授权

US10981998B2 Cross-species-specific single domain bispecific single chain antibody 有权
公开(公告)号：US10981998B2
公开(公告)日：2021-04-20
申请号：US13122280
申请日：2009-10-01
申请人： Peter Kufer , Tobias Raum , Roman Kischel , Ralf Lutterbüse , Patrick Hoffman , Matthias Klinger , Doris Rau , Susanne Mangold
发明人： Peter Kufer , Tobias Raum , Roman Kischel , Ralf Lutterbüse , Patrick Hoffman , Matthias Klinger , Doris Rau , Susanne Mangold
IPC分类号： C07K16/28
摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain consisting of one antibody variable domain capable of binding to an epitope of the human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention further relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3ϵ (epsilon) chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain consisting of one antibody variable domain capable of binding to an epitope of a human and a non-chimpanzee primate tumor target antigen. The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

18. 发明授权

US09587036B2 Cross-species-specific PSMAxCD3 bispecific single chain antibody 有权
标题翻译：跨物种特异性PSMAxCD3双特异性单链抗体
公开(公告)号：US09587036B2
公开(公告)日：2017-03-07
申请号：US13638223
申请日：2011-04-01
申请人： Peter Kufer , Ralf Lutterbuese , Matthias Klinger , Petra Fluhr , Doris Rau , Susanne Hausmann , Carola Steiger , Tobias Raum , Patrick Hoffmann , Roman Kischel , Evelyne Schaller , Susanne Mangold
发明人： Peter Kufer , Ralf Lutterbuese , Matthias Klinger , Petra Fluhr , Doris Rau , Susanne Hausmann , Carola Steiger , Tobias Raum , Patrick Hoffmann , Roman Kischel , Evelyne Schaller , Susanne Mangold
IPC分类号： C07K16/46 , A61K39/395 , C07K16/28 , C07K16/30
CPC分类号： C07K16/468 , C07K16/2809 , C07K16/30 , C07K16/3069 , C07K2317/31 , C07K2317/33 , C07K2317/622
摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.
摘要翻译：本发明涉及双特异性单链抗体分子，其包含能够结合人和非黑猩猩灵长类CD3ε链的表位的第一结合结构域，其中所述表位是包含在SEQ ID NO：1中的氨基酸序列的一部分身份证号 2,4,6和8以及能够结合前列腺特异性膜抗原（PSMA）的第二结合结构域。本发明还提供了编码所述双特异性单链抗体分子以及载体和宿主细胞的核酸及其生产方法。本发明还涉及包含所述双特异性单链抗体分子的药物组合物和所述双特异性单链抗体分子的医学应用。

19. 发明申请

US20120244162A1 CROSS-SPECIES-SPECIFIC BISPECIFIC BINDERS 审中-公开
标题翻译：跨物种特异性双重绑定
公开(公告)号：US20120244162A1
公开(公告)日：2012-09-27
申请号：US13408363
申请日：2012-02-29
申请人： Peter KUFER , Tobias Raum , Roman Kischel , Ralf Lutterbüse , Patrick Hoffmann , Matthias Klinger , Doris Rau , Susanne Mangold
发明人： Peter KUFER , Tobias Raum , Roman Kischel , Ralf Lutterbüse , Patrick Hoffmann , Matthias Klinger , Doris Rau , Susanne Mangold
IPC分类号： C07K16/46 , A61K39/395 , A61P35/00 , C12N1/19 , C12N15/63 , C12P21/00 , C12N1/21 , C12N5/10 , C12N15/13 , A61P37/00
CPC分类号： C07K16/2809 , C07K16/2863 , C07K16/30 , C07K16/3053 , C07K16/32 , C07K16/40 , C07K16/4291 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/73 , C07K2317/90 , C07K2317/92 , C07K2319/32 , C07K2319/43
摘要： The present invention relates to a polypeptide comprising a first human binding domain capbable of binding to an epitope of human and non-chimpanzee CD3ε (epsilon) chain and a second binding domain capable of binding to EGFR, Her2/neu or IgE of a human and/or a non-chimpanzee primate as well as to a process for the production of the mentioned polypeptide. The invention further relates to nucleic acid sequences encoding the polypeptide, to vectors comprising the nucleic acid sequences and to host cells comprising the nucleic acid sequences or vectors containing the nucleic acid sequences. In another aspect, the invention provides for a pharmaceutical composition comprising the polypeptide and methods of medical treatment or use of the polypeptide.
摘要翻译：本发明涉及包含可与人和非黑猩猩CD3抗原表位结合的第一人结合结构域的多肽; （ε）链和能够结合人和/或非黑猩猩灵长类动物的EGFR，Her2 / neu或IgE的第二结合结构域以及生产所述多肽的方法。本发明还涉及编码该多肽的核酸序列，包含核酸序列的载体和包含核酸序列或含有该核酸序列的载体的宿主细胞。另一方面，本发明提供了包含该多肽的药物组合物和该多肽的医学治疗或使用方法。

20. 发明申请

US20120121600A1 PHARMACEUTICAL ANTIBODY COMPOSITIONS WITH RESISTANCE TO SOLUBLE CEA 有权
标题翻译：具有抗溶性CEA的药物抗体组合物
公开(公告)号：US20120121600A1
公开(公告)日：2012-05-17
申请号：US13324823
申请日：2011-12-13
申请人： Doris RAU , Susanne Mangold , Peter Kufer , Tobias Raum
发明人： Doris RAU , Susanne Mangold , Peter Kufer , Tobias Raum
IPC分类号： A61K39/395 , A61P35/00 , C07K16/32
CPC分类号： C07K16/3007 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732
摘要： The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising an IgG1 antibody specifically binding to human CEA, wherein the variable region of said IgG1 antibody comprises at least (i) a CDR-H1 having the amino acid sequence “SYWMH” and a CDR-H2 having the amino acid sequence “FIRNKANGGTTEYAASVKG” and a CDR-H3 having the amino acid sequence “DRGLRFYFDY” or (ii) a CDR-H1 having the amino acid sequence “TYAMH” and a CDR-H2 having the amino acid sequence “LISNDGSNKYYADSVKG” and a CDR-H3 having the amino acid sequence “DRGLRFYFDY”. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the IgG1 antibody molecules bearing specificities for the human CEA antigen are disclosed.
摘要翻译：本发明涉及用于治疗人类上皮肿瘤的药物组合物，所述药物组合物包含与人CEA特异性结合的IgG1抗体，其中所述IgG1抗体的可变区至少包含（i）具有氨基酸序列“SYWMH”和具有氨基酸序列“FIRNKANGGTTEYAASVKG”的CDR-H2和具有氨基酸序列“DRGLRFYFDY”的CDR-H3或（ii）具有氨基酸序列“TYAMH”的CDR-H1和具有氨基酸序列“LISNDGSNKYYADSVKG”的CDR-H2和具有氨基酸序列“DRGLRFYFDY”的CDR-H3。此外，公开了用于生产所述药物组合物的方法以及具有人CEA抗原特异性的IgG1抗体分子的医疗/药物用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式